NASDAQ:CPRXCatalyst Pharmaceuticals Stock Price, Forecast & News

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CPRX shares have increased by 22.4% and is now trading at $4.31. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.01. The biopharmaceutical company had revenue of $29.14 million for the quarter, compared to the consensus estimate of $31.68 million. Catalyst Pharmaceuticals had a return on equity of 52.28% and a net margin of 36.09%. View Catalyst Pharmaceuticals' earnings history.

4 brokers have issued 12-month target prices for Catalyst Pharmaceuticals' shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 120.4% from the stock's current price. View analysts' price targets for Catalyst Pharmaceuticals.

Media headlines about CPRX stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutCatalyst Pharmaceuticals.

Catalyst Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 12,210,000 shares, a decrease of 12.8% from the April 30th total of 14,010,000 shares. Based on an average daily trading volume, of 2,110,000 shares, the days-to-cover ratio is presently 5.8 days. Currently, 12.7% of the company's shares are sold short. View Catalyst Pharmaceuticals' Current Options Chain.

Some companies that are related to Catalyst Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Epizyme (EPZM), Zymeworks (ZYME), Corcept Therapeutics (CORT), Xencor (XNCR), Heron Therapeutics (HRTX), Ligand Pharmaceuticals (LGND), Zogenix (ZGNX), Dicerna Pharmaceuticals (DRNA), Theravance Biopharma (TBPH), Ironwood Pharmaceuticals (IRWD), Opko Health (OPK), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB) and Akebia Therapeutics (AKBA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), SCYNEXIS (SCYX) and Micron Technology (MU).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.19%), State Street Corp (7.20%), Morgan Stanley (2.62%), Morgan Stanley (2.62%), Geode Capital Management LLC (1.49%) and Schroder Investment Management Group (1.28%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Gary Ingenito and Patrick J Mcenany. View institutional ownership trends for Catalyst Pharmaceuticals.

CPRX stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Squarepoint Ops LLC, Two Sigma Investments LP, Rafferty Asset Management LLC, Wells Fargo & Company MN, Voloridge Investment Management LLC, Morgan Stanley, and Morgan Stanley. View insider buying and selling activity for Catalyst Pharmaceuticals.

CPRX stock was purchased by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Sontag Advisory LLC, Federated Hermes Inc., Acadian Asset Management LLC, Los Angeles Capital Management & Equity Research Inc., Russell Investments Group Ltd., AQR Capital Management LLC, and BNP Paribas Arbitrage SA. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, and Patrick J Mcenany. View insider buying and selling activity for Catalyst Pharmaceuticals.

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CPRX stock can currently be purchased for approximately $4.31.

Catalyst Pharmaceuticals has a market capitalization of $445.74 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]